Arvinas Announces Retirement of Chief Executive Officer and Succession Plan
Arvinas (NASDAQ:ARVN), a clinical-stage biotech company focused on targeted protein degradation, announced that CEO and President John Houston, Ph.D. will retire from his executive roles following the appointment of a successor. Dr. Houston will continue serving as Chairperson of the Board of Directors.
During his 8-year tenure, Houston led Arvinas through significant achievements, including launching six programs into clinical trials, reporting the first positive pivotal Phase 3 trial for a PROTAC degrader, and demonstrating the first oral PROTAC's pharmacodynamic activity in the central nervous system. The Board of Directors has initiated a search for a new CEO to ensure continued leadership.
Arvinas (NASDAQ:ARVN), un'azienda biotech in fase clinica specializzata nella degradazione mirata delle proteine, ha annunciato che il CEO e Presidente John Houston, Ph.D. si ritirerà dai suoi ruoli esecutivi dopo la nomina di un successore. Il dottor Houston continuerà a ricoprire il ruolo di Presidente del Consiglio di Amministrazione.
Durante il suo mandato di 8 anni, Houston ha guidato Arvinas attraverso importanti traguardi, tra cui il lancio di sei programmi in studi clinici, la segnalazione del primo esito positivo in uno studio pivotale di Fase 3 per un degrader PROTAC, e la dimostrazione dell'attività farmacodinamica del primo PROTAC orale nel sistema nervoso centrale. Il Consiglio di Amministrazione ha avviato la ricerca di un nuovo CEO per garantire una leadership continua.
Arvinas (NASDAQ:ARVN), una empresa biotecnológica en etapa clínica centrada en la degradación dirigida de proteínas, anunció que el CEO y Presidente John Houston, Ph.D. se retirará de sus cargos ejecutivos tras el nombramiento de un sucesor. El Dr. Houston continuará sirviendo como Presidente del Consejo de Administración.
Durante su mandato de 8 años, Houston lideró a Arvinas a través de logros significativos, incluyendo el lanzamiento de seis programas en ensayos clínicos, reportando el primer ensayo pivotal de Fase 3 positivo para un degradador PROTAC, y demostrando la actividad farmacodinámica del primer PROTAC oral en el sistema nervioso central. La Junta Directiva ha iniciado la búsqueda de un nuevo CEO para asegurar un liderazgo continuo.
Arvinas (NASDAQ:ARVN)는 표적 단백질 분해에 중점을 둔 임상 단계 바이오테크 기업으로, CEO 겸 사장 John Houston 박사가 후임자 임명 후 경영진 역할에서 은퇴할 것이라고 발표했습니다. 휴스턴 박사는 계속해서 이사회 의장으로 활동할 예정입니다.
8년간의 재임 기간 동안 휴스턴은 Arvinas를 이끌며 여섯 개의 프로그램을 임상 시험에 진입시키고, PROTAC 분해제에 대한 최초의 긍정적인 3상 임상 시험 결과를 보고했으며, 최초 경구용 PROTAC의 중추신경계 약력학적 활성을 입증했습니다. 이사회는 지속적인 리더십을 위해 새로운 CEO를 찾기 시작했습니다.
Arvinas (NASDAQ:ARVN), une entreprise biotechnologique en phase clinique spécialisée dans la dégradation ciblée des protéines, a annoncé que le PDG et président John Houston, Ph.D. prendra sa retraite de ses fonctions exécutives suite à la nomination d’un successeur. Le Dr Houston continuera de siéger en tant que président du conseil d'administration.
Au cours de ses 8 années de mandat, Houston a mené Arvinas à travers d’importantes réussites, notamment le lancement de six programmes en essais cliniques, le rapport du premier essai pivot de phase 3 positif pour un dégradeur PROTAC, et la démonstration de l’activité pharmacodynamique du premier PROTAC oral dans le système nerveux central. Le conseil d’administration a lancé la recherche d’un nouveau PDG afin d’assurer une continuité dans le leadership.
Arvinas (NASDAQ:ARVN), ein biotechnologisches Unternehmen in der klinischen Phase mit Fokus auf gezielten Proteinabbau, gab bekannt, dass CEO und Präsident John Houston, Ph.D. nach der Ernennung eines Nachfolgers von seinen Führungspositionen zurücktreten wird. Dr. Houston wird weiterhin als Vorsitzender des Vorstands tätig sein.
Während seiner achtjährigen Amtszeit führte Houston Arvinas zu bedeutenden Erfolgen, darunter der Start von sechs Programmen in klinische Studien, die Meldung der ersten positiven entscheidenden Phase-3-Studie für einen PROTAC-Degrader und den Nachweis der pharmakodynamischen Aktivität des ersten oralen PROTAC im zentralen Nervensystem. Der Vorstand hat die Suche nach einem neuen CEO eingeleitet, um eine kontinuierliche Führung sicherzustellen.
- None.
- Potential disruption during CEO transition period
- Loss of experienced executive leadership with 35+ years of industry experience
– John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor –
– Dr. Houston to Remain Chairperson of Arvinas Board of Directors –
– Arvinas Board of Directors to Lead Search for CEO Replacement –
NEW HAVEN, Conn., July 09, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that John Houston, Ph.D., Chairperson, Chief Executive Officer (CEO) and President at Arvinas, has informed the Board of Directors of his plans to retire from his role as President and CEO following a search for, and the appointment of, the Company’s new CEO. The Arvinas Board of Directors has begun a search for a new CEO, and Dr. Houston will remain Chairperson of Arvinas’ Board of Directors upon retiring as President and CEO.
“On behalf of the Arvinas Board of Directors, I sincerely thank John for his exceptional leadership and significant contributions to Arvinas over the past 8 years and his commitment to a smooth transition as we identify his successor,” said Briggs Morrison, M.D., Arvinas Board Member and Lead Independent Director. “John has guided Arvinas through a substantial number of ‘firsts’ for PROTACs in the industry, from the first to enter the clinic to the first positive pivotal Phase 3 trial and the first new drug application. John and Arvinas have turned targeted protein degradation into a well-known modality across several therapeutic areas. Due to his efforts, the Company is well positioned to benefit many patients in the years to come. As we undertake the process of identifying a new CEO, the Board is committed to conducting a thoughtful search to ensure continued strong leadership. We look forward to continuing our work with John in his capacity as Chairperson.”
With more than 35 years of experience in the pharmaceutical and biotech industries, Dr. Houston joined Arvinas in January 2017 as President of Research and Development and Chief Scientific Officer responsible for leading the discovery, translational, and early clinical development research efforts. In September 2017, Dr. Houston was appointed President and CEO, and in 2023 he was named Arvinas’ Chairperson.
During his tenure as CEO, Dr. Houston has been instrumental in Arvinas’ success moving six programs into the clinic, reporting the results of the first positive pivotal Phase 3 trial for a PROTAC, and reporting for the first time that an orally administered PROTAC can achieve pharmacodynamic activity in the central nervous system.
“It has been an honor to lead Arvinas alongside incredibly talented colleagues and a supportive Board of Directors,” said Dr. Houston. “I look forward to remaining a part of Arvinas as Chairperson and I’m confident in the Company’s ability to improve the lives of patients with serious diseases through our revolutionary PROTAC protein degradation platform. From initiating the first oral PROTAC degrader in clinical trials to delivering positive topline results, it is evident that Arvinas has and will continue to push the boundaries of what’s possible.”
About Arvinas
Arvinas (Nasdaq: ARVN) is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through its PROTAC protein degrader platform, Arvinas is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Arvinas is currently progressing multiple investigational drugs through clinical development programs, including vepdegestrant, targeting the estrogen receptor for patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-393, targeting BCL6 for relapsed/refractory non-Hodgkin lymphoma; ARV-102, targeting LRRK2 for neurodegenerative disorders; and ARV-806, targeting KRAS G12D for mutated cancers, including pancreatic and colorectal cancers. Arvinas is headquartered in New Haven, Connecticut. For more information about Arvinas, visit www.arvinas.com and connect on LinkedIn and X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding: John Houston, Ph.D.’s retirement from his role as President and Chief Executive Officer (“CEO”) and his continuing role as chairperson of the Arvinas Board of Directors, statements regarding Arvinas’ search for and succession plan for the CEO position of Arvinas; Arvinas being well positioned to benefit many patients in the years to come; and the belief that Arvinas will continue to push the boundaries of what is possible. All statements, other than statements of historical fact, contained in this press release, including statements regarding Arvinas’ strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “target,” “goal,” “potential,” “will,” “would,” “could,” “should,” “look forward,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
Arvinas may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements, and you should not place undue reliance on such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Arvinas makes as a result of various risks and uncertainties, including but not limited to: risks related to the ability to identify and attract a qualified candidate to serve as Arvinas’ next CEO; and other important factors discussed in the “Risk Factors” section of Arvinas’ Annual Report on Form 10-K for the year ended December 31, 2024, Arvinas’ Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and subsequent other reports on file with the U.S. Securities and Exchange Commission. The forward-looking statements contained in this press release reflect Arvinas’ current views with respect to future events, and Arvinas assumes no obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release.
Contacts:
Investors:
Jeff Boyle
+1 (347) 247-5089
Jeff.Boyle@arvinas.com
Media:
Kirsten Owens
+1 (203) 584-0307
Kirsten.Owens@arvinas.com
FAQ
Why is John Houston stepping down as CEO of Arvinas (ARVN)?
What are the major achievements of Arvinas under John Houston's leadership?
Who will be the next CEO of Arvinas (ARVN)?
What is John Houston's future role at Arvinas?
How long has John Houston been with Arvinas (ARVN)?
